title: Zoledronic acid in treatment of bone lesions by Langerhans cell histiocytosis.
abstract: Langerhans cell histiocytosis (LCH) is a rare disease, probably an atypical myeloproliferative syndrome, with variable clinical presentation and behavior. In this report, we focus on bone involvement by LCH and treatment with zoledronic acid in six patients as they progressed after chemotherapy and radiotherapy. Zoledronic acid appeared safe and produced significant relief in pain.
authors.affiliation: Medical Oncology Unit, S. Giovanni di Dio Hospital, Frattamaggiore, Naples, Italy. lilianamontella@libero.it
authors.forename: Liliana
authors.initials: L
authors.lastname: Montella
authors.forename: Carmela
authors.initials: C
authors.lastname: Merola
authors.forename: Geraldina
authors.initials: G
authors.lastname: Merola
authors.forename: Luigi
authors.initials: L
authors.lastname: Petillo
authors.forename: Giovannella
authors.initials: G
authors.lastname: Palmieri
mesh_terms: D000328:Adult; D050071:Bone Density Conservation Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001842:Bone and Bones / Q000187:drug effects / Q000473:pathology*; D004164:Diphosphonates / Q000494:pharmacology / Q000627:therapeutic use*; D018450:Disease Progression; D005260:Female; D006646:Histiocytosis, Langerhans-Cell / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011877:Radionuclide Imaging; D055815:Young Adult; D000077211:Zoledronic Acid
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid